IL6 and breast cancer: Gyamfi et al., 2018 and Sheng et al., 2018 reported that the pro-inflammatory cytokine IL-6 has been directly linked to breast cancer progression and risk. DMBA toxicity is known to trigger the release of inflammatory cytokines such as TNF-α, and IL-6 in breast cancer (Ramadhani et al., 2020).